Evidence map›Paper›PMID 26132521›Full record

ArticleFuture medicinal chemistry2015

Gold nanoparticles to improve HIV drug delivery.

Carolina Garrido, Carrie A Simpson, Noelle P Dahl, Jamee Bresee, Daniel C Whitehead, Erick A Lindsey, Tyler L Harris, Candice A Smith, Carly J Carter, Daniel L Feldheim and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Carolina GarridoDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7005, USA.
Carrie A SimpsonDepartment of Chemistry, University of Colorado, Boulder, CO 80309, USA.
Noelle P DahlDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7005, USA.
Jamee BreseeDepartment of Chemistry, University of Colorado, Boulder, CO 80309, USA.
Daniel C WhiteheadDepartment of Chemistry, North Carolina State University, Raleigh, NC 27607, USA.
Erick A LindseyDepartment of Chemistry, North Carolina State University, Raleigh, NC 27607, USA.
Tyler L HarrisDepartment of Chemistry, North Carolina State University, Raleigh, NC 27607, USA.
Candice A SmithDepartment of Chemistry, University of Colorado, Boulder, CO 80309, USA.
Carly J CarterDepartment of Chemistry, University of Colorado, Boulder, CO 80309, USA.
Daniel L FeldheimDepartment of Chemistry, University of Colorado, Boulder, CO 80309, USA.
Christian MelanderDepartment of Chemistry, North Carolina State University, Raleigh, NC 27607, USA.
David M MargolisDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7005, USA.

Funding

Nanocrystal delivery to the CNS to improve HIV therapyR01MH085597 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2009 to 2013
$1.7M
NIMH NIH HHS R01 MH085597
6 · The paper itself

Abstract

backgroundAntiretroviral therapy (ART) has improved lifespan and quality of life of patients infected with the HIV-1. However, ART has several potential limitations, including the development of drug resistance and suboptimal penetration to selected anatomic compartments. Improving the delivery of antiretroviral molecules could overcome several of the limitations of current ART. RESULTS &

conclusionTwo to ten nanometer diameter inorganic gold crystals serve as a base scaffold to combine molecules with an array of properties in its surface. We show entry into different cell types, antiviral activity of an HIV integrase inhibitor conjugated in a gold nanoparticle and penetration into the brain in vivo without toxicity. Herein, gold nanoparticles prove to be a promising tool to use in HIV therapy.

Indexed as

AnimalsAnti-HIV AgentsBrainDrug CarriersEndothelial CellsFemaleGoldHIV-1HIV Core Protein p24HIV InfectionsHumansLeukocytes, MononuclearMacrophagesMetal NanoparticlesMiceMice, Inbred BALB CAnti-HIV AgentsDrug CarriersGoldHIV Core Protein p24Raltegravir Potassium

Identifiers

PMID26132521
PMCPMC4501014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.